ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NICE recommends against Opdivo for classical Hodgkin lymphoma
March 16, 2017The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab)... -
NICE asks for more data on Opdivo
March 16, 2017The National Institute for Health and Care Excellence has published draft guidelines recommending that Bristol ... -
Bristol-Myers Squibb won't seek accelerated US approval of Opdivo, Yervoy combination in first-line
January 22, 2017Bristol-Myers Squibb announced that it will not pursue an accelerated regulatory pathway for the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line lung cancer in the US based on a review of current data. -
Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gast
January 20, 2017Opdivo demonstrated a 37% reduction in the risk of death compared to placebo. -
BMS and Janssen to collaborate to evaluate Opdivo in combination with Darzalex
January 09, 2017Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.
Pharma Sources Insight January 2025
